One of Canada’s longest running and top fundraising events returned to in-person Rides in Montréal and Toronto, on October 6 and 13, 2022 respectively, along with virtual rides across the country. […]
A key tenet of JDRF’s research funding strategy is that there are multiple pathways to cures for type 1 diabetes (T1D), one of which includes screening for risk and use […]
Karoliina Tuomela is a postdoctoral researcher at the JDRF Centre of Excellence at the University of British Columbia, and the first recipient of a J. Andrew McKee Fellowship in Type […]
This blog contains content relating to early mortality due to Type 1 Diabetes, which may be confronting and distressing to some readers. Please exercise caution and care when engaging with […]
September 23, 2022 JDRF is deeply saddened by the loss of an incredible individual who made an unparalleled impact at JDRF, Peter Oliver. “Peter possessed a multitude of qualities that defined […]
The following is sponsored content developed in partnership with AMG Medical Low blood glucose—also known as hypoglycemia—can be one of the most challenging, stressful, and often scary parts of living […]
JDRF’s #AccessForAll advocacy campaign aims to make type 1 diabetes (T1D) technology affordable and accessible for all Canadians living with the disease. With support from the T1D community, JDRF seeks […]
JDRF Canada is thrilled to partner with Michael Smith Health Research BC to award type 1 diabetes (T1D) researcher Dr. Tricia Tang a Health Research BC Health Professional-Investigator (HP-I) award. […]
JDRF congratulates the McGill University Health Centre (MUHC) on its recent mandate to provide islet transplantation for persons with T1D in Quebec. This designation by Quebec’s Ministry of Health and […]
Sébastien was diagnosed with type 1 diabetes (T1D) in 2002. He made a commitment to himself then that T1D would never keep him from living life to the fullest, and […]
Update: July 15, 2022 On Thursday, July 14, 2022 Health Canada approved the Moderna Spikevax Covid-19 vaccine for children aged six months to five years old. This makes approximately 1.7 […]
On Monday July 11, 2022, Vertex Pharmaceuticals announced they acquired ViaCyte for $320 million in cash to help speed up the development of VX-880, Vertex’s stem cell-derived therapy for people […]
